3-amino-2,3-dideoxyinositol: intermediate in biosynthesis of 2-deoxystreptamine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-deoxy-scyllo-inosamine : An amino cyclitol that is scyllo-inosamine in which the 2-hydroxy group is substituted by hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 194428 |
| CHEBI ID | 65046 |
| MeSH ID | M0089112 |
| Synonym |
|---|
| s 11p |
| C17580 |
| 2-deoxy-scyllo-inosamine |
| 72075-06-0 |
| 75419-36-2 |
| (1r,2s,3s,4r,5s)-5-aminocyclohexane-1,2,3,4-tetrol |
| 25w , |
| CHEBI:65046 |
| d-myo-inositol, 3-amino-2,3-dideoxy- |
| 1-deamino-2-deoxy-1-hydroxystreptamine |
| dl-scyllo-inositol, 1-amino-1,2-dideoxy- |
| s-11p |
| (1l)-1,3,5/2,4,5-aminocyclohexanetetrol |
| 3-amino-2,3-dideoxyinositol |
| 2,3,4,5-tetrahydrocyclohexylamine 3,5/2,4 |
| s-11-p |
| d-myo-inositol,3-amino-2,3-dideoxy- |
| 76188-89-1 |
| 5-aminocyclohexane-1,2,3,4-tetrol |
| Q27133607 |
| (1r,2s,3s,4r,5s)-5-aminocyclohexane-1,2,3,4-tetraol |
| DTXSID30992803 |
| rel-(1r,2s,3s,4r,5s)-5-aminocyclohexane-1,2,3,4-tetraol |
| STARBLD0001024 |
| Class | Description |
|---|---|
| amino cyclitol | Any cyclitol having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||